Levide (Levosulpiride)

Levosulpiride is indicated for several psychiatric and gastrointestinal conditions that involve dopaminergic dysregulation.

• Schizophrenia: reduces positive symptoms such as hallucinations and delusions, and contributes to overall psychotic stability.
• Depression: augments antidepressant response and may improve mood and motivation in patients with depressive disorders.
• Functional dyspepsia: alleviates upper abdominal discomfort, early satiety and post‑prandial fullness associated with dyspeptic syndrome.
• Gastro‑oesophageal reflux disease: enhances gastric emptying, improves lower esophageal sphincter tone and reduces reflux episodes.

• Levosulpiride acts as a selective antagonist of dopamine D2 receptors in the central nervous system, thereby modulating dopaminergic neurotransmission implicated in psychosis. In the gastrointestinal tract it exerts prokinetic activity by blocking peripheral D2 receptors, which enhances acetylcholine release and promotes gastric motility. The drug’s high affinity for D2 receptors results in a dose‑dependent reduction of dopamine‑mediated signaling without significant antagonism of other neurotransmitter systems.

Levosulpiride may be associated with a range of adverse reactions, which are generally classified by frequency and severity.

Common Side Effects

• Drowsiness: mild sedation or fatigue that may affect daily activities.
• Extrapyramidal symptoms: tremor, rigidity, akathisia or mild parkinsonian features.
• Nausea: transient gastrointestinal upset, often resolving with continued therapy.
• Elevated prolactin: menstrual irregularities, galactorrhea or breast tenderness.
• Dry mouth: reduced salivation leading to oral discomfort.
• Weight gain: modest increase in body weight observed in some patients.

Serious or Rare Side Effects

• Neuroleptic malignant syndrome: life‑threatening hyperthermia, muscle rigidity and autonomic instability.
• Severe depression or suicidal ideation: worsening of mood symptoms requiring immediate medical attention.
• Cardiac arrhythmias: QT interval prolongation or other rhythm disturbances that may be fatal.
• Hyperglycemia: significant rise in blood glucose levels, especially in diabetic patients.
• Hepatotoxicity: elevated liver enzymes or hepatic injury in rare cases.

When prescribing levosulpiride, clinicians should consider several precautionary measures to ensure safe use.

• Pregnancy: use only if potential benefit justifies risk; data are limited.
• Breastfeeding: avoid or discontinue nursing as drug may be excreted in milk.
• Elderly patients: start at lower dose and monitor for extrapyramidal symptoms.
• Renal impairment: dose adjustment may be required; assess renal function.
• Concomitant CNS depressants: monitor for enhanced sedation or respiratory depression.
• Store at ambient temperature: keep below 25°C, protect from moisture and light in original packaging.

Levosulpiride can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Antipsychotics with strong D2 antagonism (e.g., haloperidol): may increase risk of extrapyramidal symptoms.
• MAO inhibitors: combined use can precipitate severe hypertension or serotonin syndrome.
• QT‑prolonging agents (e.g., erythromycin, fluoroquinolones): additive risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely)

• CYP2D6 substrates (e.g., metoprolol): levosulpiride may inhibit metabolism, raising plasma levels.
• Anticholinergic drugs (e.g., atropine): may counteract prokinetic effects.
• CNS depressants (e.g., benzodiazepines): enhanced sedation may occur.
• Hormonal contraceptives: elevated prolactin may reduce contraceptive efficacy.